Background: Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first-and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38. Methods: Of the 30 white cancer patients, 27 received at least two treatments with irinotecan administered as one 90-minute infusion (dose, 600 mg) with 3 weeks between treatments, and three received only one treatment. Before the first and second treatments, patients underwent an erythromycin breath test and a midazolam clearance test as phenotyping probes for CYP3A4. Erythromycin metabolism was assessed as the area under the curve for the flux of radioactivity in exhaled CO 2 within 40 minutes after administration of [N-methyl-14 C]erythromycin. Midazolam and irinotecan were measured by high-performance liquid chromatography. Genomic DNA was isolated from blood and screened for genetic variants in CYP3A4 and UGT1A1. All statistical tests were two-sided. Results: CYP3A4 activity varied sevenfold (range ‫؍‬ 0.223%-1.53% of dose) among patients, whereas midazolam clearance varied fourfold (range ‫؍‬ 262-1012 mL/min), although intraindividual variation was small. Erythromycin metabolism was not statistically significantly associated with irinotecan clearance (P ‫؍‬ .090), whereas midazolam clearance was highly correlated with irinotecan clearance (r ‫؍‬ .745, P<.001). In addition, the presence of a UGT1A1 variant with a (TA) 7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng · h/mL, 95% confidence interval 
The topoisomerase I inhibitor irinotecan has been approved in the United States as a second-line treatment for advanced colorectal cancer that is refractory to fluorouracil and as first-line treatment in combination with fluorouracil-leucovorin for metastatic colorectal cancer (1) . Apart from antitumor activity in colorectal cancer, single-agent irinotecan is also moderately active in several other solid malignancies, including breast cancer (2) , relapsed or refractory non-Hodgkin lymphoma (3) , and lung cancer (4) . Irinotecan is unique among camptothecin analogues in that it must first be converted by a carboxylesteraseconverting enzyme to the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) (5) . Despite much research into the complex pharmacokinetic profile and pharmacodynamic effects of irinotecan, unpredictable and severe side effects are still commonly observed (6, 7) .
Irinotecan pharmacokinetic variability between individuals is large. Pathways that eliminate irinotecan contain the cytochrome P450 3A subfamily members CYP3A4 and CYP3A5 (collectively referred to as CYP3A); the uridine diphosphate glucuronosyltransferase 1A subfamily members UGT1A1, UGT1A3, UGT1A7, and UGT1A9 (collectively referred to as UGT1A); and drug transporting proteins, including ABCB1 (P-glycoprotein) (5) (Fig. 1) . Recent investigations have also indicated that genetic polymorphisms (8) , herbal supplements (9) , and concomitantly administered allopathic drugs (10) can alter the activity and/or expression levels of these proteins and change the rate of irinotecan elimination. Thus far, only limited attempts have been made to incorporate this knowledge into clinical practice. Because dosing strategies that are based on body surface area do not reduce interindividual variability in irinotecan pharmacokinetics (11) (12) (13) , other measures to predict the pharmacologic profile of irinotecan in individual patients are needed. One possibility is to assess the phenotype of CYP3A because CYP3A is involved in the metabolism of about half of all prescribed drugs (14) and plays a principal role in the metabolism of irinotecan (5) . In vivo probe drugs such as cortisol, dextromethorphan, erythromycin, and midazolam are widely used for evaluating CYP3A activity in humans (15) (16) (17) , and such probes accurately predict the activity of CYP3A (18 -20) and the clearance of docetaxel, another anticancer drug that is a CYP3A substrate (21) (22) (23) (24) . Consequently, we prospectively explored the relationship between CYP3A phenotype, as assessed with the probe drugs erythromycin and midazolam, and the metabolism of irinotecan and its active metabolite SN-38 by white patients with cancer.
PATIENTS AND METHODS

Treatment of Patients
Eligible patients had a solid tumor for which irinotecan was considered the treatment of choice or for which no standard treatment option was available. Patients were treated with irinotecan (Aventis, Hoevelaken, The Netherlands) once every 3 weeks as a 90-minute intravenous infusion at a fixed dose of 600 mg. If excessive toxicity (e.g., diarrhea and neutropenia) was detected, the next course was postponed for a week and/or the dose was reduced by 25%. Thirty cancer patients received irinotecan chemotherapy; all but three received two treatments. Eligibility and exclusion criteria (including acceptable liver functions and a World Health Organization performance score of Յ1), premedication, and protocols for treatment of druginduced side effects (e.g., diarrhea with the use of loperamide and/or antibiotics) were identical to those used earlier (25) . No patient was allowed to use drugs, food supplements, and/or herbal preparations that were known to interfere with the function or expression of proteins involved in irinotecan disposition. The clinical protocol was approved by the Erasmus Medical Center Ethics Board, and all patients provided written informed consent before study entry.
Erythromycin Breath Test
Five microcuries (Ci; 0.07 mg or 0.1 mol) of [N-methyl- 14 C]erythromycin (American Radiolabeled Chemicals, St. Louis, MO) in 4 mL of a solution of 2.5% glucose and 0.45% sodium chloride (final erythromycin concentration, 17.5 g/mL or 1.19 Ci/g) was injected intravenously through an infusion set in less than 30 seconds, 4 -8 days before the first treatment with irinotecan. In half of the patients, this test was repeated before the second course; in the other half, a second midazolam clearance test was given. The metabolism of erythromycin in the liver involves the CYP3A4-catalyzed cleavage of the N-methyl group from erythromycin and, after a series of non-rate-limiting steps, the formation of CO 2 from the cleaved formaldehyde (20) . Inclusion of 14 C-labeled N-methyl moieties in erythromycin results in the production of 14 CO 2 (26) . Patients exhaled 14 CO 2 through a drinking straw into a solution of 2.00 mL of 1 M hyamine hydroxide in methanol (Packard Instrument, Meriden, CT) and 2 mL of thymolphthalein (60 mg/L in ethanol).
14 CO 2 and CO 2 in the breath sample were absorbed by the hyamine hydroxide, and the indicator thymolphthalein (60 mg/L in ethanol) changed color from blue to clear when the hyamine hydroxide was saturated with CO 2 . Aspiration of liquid as the patient breathed was prevented by safety valves. After combining the 4-mL breath sample solution with 5 mL of Insta-Gel Plus liquid scintillation fluid (Packard), we determined the amount of 14 CO 2 in a breath sample by liquid scintillation counting on a Packard TRI-CARB Liquid Scintillation Analyzer 1900 TR, as described elsewhere (27) . The amount of radioactivity was expressed as disintegrations per minute (dpm where the first two terms, (dpm tx Ϫ dpm t0 )/2.222 ϫ 10 6 dpm/ Ci and 1/2.00 ml ϫ 0.972 M CO 2 , refer to the measured dose in microcuries (first term) per captured millimole (second term) of CO 2 at time tx, and in the third term 1.19 Cig ϫ ⌬weight is the administered dose in microcuries, and 100 corrects for percentage. In the equation, dpm tx is the amount of radioactivity (expressed in disintegrations per minute) for each breath sample obtained, and weight is the mass (expressed in grams) of solution injected. The product of the first three terms is the percentage of administered dose per exhaled millimole of CO 2 at time x. Multiplying this product by the fourth term (5 mmol CO 2 / min/m 2 ϫ BSA) corrects for CO 2 output of individuals on the basis of 5 mmol of CO 2 exhaled per minute per square meter of body surface area (BSA), to give the flux of exhaled 14 C expressed as percentage of the dose per minute (28) . The most commonly used parameter from the erythromycin breath test is CER 0 -40 , the area under the curve for the flux of radioactivity ( 14 C) in exhaled CO 2 from 0 to 40 minutes (19) , and it served as the primary parameter to predict total body clearance of irinotecan. -piperidino]-carbonyloxycamptothecin; hCE1/2 ϭ human carboxylesterase isoforms 1 and 2; CYP3A4/5 ϭ cytochrome P450 isoforms 3A4 and 3A5; UGT1A1/7/9 ϭ UDP glucuronosyltransferase isoforms 1A1, 1A7, and 1A9; ABCB1 ϭ P-glycoprotein; ABCC2 ϭ multidrug resistanceassociated protein 2 (cMOAT); ABCG2 ϭ breast cancer-resistance protein.
Irinotecan is eliminated in all those compartments (blood, hepatocyte, and bile) where the mentioned metabolites (black names) are formed by use of enzymes and excreted by ABC transporters (white names).
Midazolam Clearance Test
Midazolam (0.025 mg/kg of body weight, Roche Laboratories, Mijdrecht, The Netherlands) was injected intravenously within a 30-second period, 4 -8 days before the first treatment with irinotecan. In patients not undergoing a second erythromycin breath test, the midazolam clearance test was repeated before the second treatment with irinotecan. Blood samples of 7 mL were collected immediately before infusion and 5 and 30 minutes and 1, 2, 4, 5, and 6 hours after the infusion ended. These blood samples were centrifuged immediately after collection for 10 minutes at 2000g (4°C), and plasma supernatants were stored at Ϫ20°C on the day of collection and then at Ϫ80°C until the day of analysis. After the addition of 25 L of the internal standard (a solution of lorazepam at 4 g/mL of methanol), 600 L of plasma was extracted in one step with ethyl acetate. Midazolam and lorazepam were separated by high-performance liquid chromatography on a column (150 ϫ 4.6 mm, internal diameter) with a matrix of 5-m Zorbax Eclipse XDB-C 8 and with a mobile phase composed of methanol and 10 mM aqueous ammonium acetate (60:40, vol/vol). Column effluents were analyzed by mass spectrometry with an atmospheric pressure chemical ionization interface (29) . Calibration curves for midazolam were linear from 1.00 to 200 ng/mL. The accuracy and precision of measurements ranged from 92.8% to 112% and from 0.056% to 13.4%, respectively, for four concentrations of quality control samples analyzed in triplicate on eight separate occasions.
Irinotecan Pharmacokinetics
Blood samples of 5 mL were collected in heparin-containing tubes during the first and second irinotecan treatments at the following times: immediately before infusion; 30 minutes after the start of infusion; immediately before the end of infusion; and 10, 20, and 30 minutes and 1, 1.5, 2, 3.5, 5, 6.5, 23, 31, 47, and 55 hours after the end of infusion. In addition, patients were asked to provide a blood sample during their weekly outpatient visit on days 7, 14, and 20 after infusion. Blood samples were handled as described previously (30) , and concentrations of irinotecan, SN-38, and SN-38 glucuronide (SN-38G) were determined by reversed-phase high-performance liquid chromatography with fluorescence detection as described previously (31, 32) .
Genotyping Procedures
DNA was isolated from 0.2 mL of whole blood or plasma with a Total Nucleic Acid Extraction kit on a MagNA Pure LC (Roche Molecular Biochemicals, Mannheim, Germany) and amplified by polymerase chain reaction. Restriction fragment length polymorphism analysis was used to identify specific variations in the genes ABCB1 (i.e., ABCB1 1236C3 T [ABCB1*8], ABCB1 2677G3 A/T [ABCB1 *7] , and ABCB1 3435C3 T [ABCB1*6]), CYP3A4 (CYP3A4*1B, CYP3A4*2, CYP3A4*3, CYP3A4*17, and CYP3A4*18), and CYP3A5 (CYP3A5*3 and CYP3A5*6) (33, 34) . The number of TA repeats in the promoter of the UGT1A1 gene was determined by sizing of products from the polymerase chain reaction obtained with the UGT1A1-specific primers 5Ј-6-carboxyfluorescein-AAGTGAACTCCCTGCTACCT-3Ј and 5Ј-AAAGTGAACT CCCTGCTACC-3Ј, followed by fragment analysis carried out with the automated capillary electrophoresis instrument ABI310 (Applied BioSystems, Foster City, CA).
Pharmacokinetic Analysis
For pharmacokinetic modeling, we used a previously developed population model (35) to estimate individual pharmacokinetic parameters of irinotecan, SN-38, and SN-38G, which included the accumulated area under the plasma concentration versus time curve (AUC) and clearance. The AUC was determined for irinotecan and its metabolites in all patients from 0 to 100 hours after start of infusion for a dose corrected to 600 mg. In this analysis, interoccasion variability in the parameters was also considered. The analysis was performed with NONMEM version VI (S. L. Beal and L. B. Sheiner, San Francisco, CA). The relative extent of conversion (irinotecan to SN-38) was calculated as the ratio of the AUC of SN-38 and the AUC of irinotecan, and the relative extent of glucuronidation (SN-38 to SN-38G) was calculated as the ratio of the AUC of SN-38G and the AUC of SN-38. WinNonlin version 4.0 (Pharsight, Mountain View, CA) was used to calculate pharmacokinetics parameters for the erythromycin breath test and midazolam clearance test data. Uniform weighted percentages of the administered dose per minute (CER tx ) as input for a one-compartment model yielded the following parameters for the erythromycin breath test: the maximal CER (CER max ), t max , and its reciprocal 1/t max . The area under the CER curve from 0 to 40 minutes (CER 0 -40 ) was calculated by use of noncompartmental analysis, and the percentage of the administered dose per minute in the sample obtained at the 20-minute point was noted. The clearance was calculated as the ratio of dose and AUC extrapolated to infinity obtained from a linear one-compartment model. For the midazolam clearance test, the clearance and the midazolam concentration obtained at the 4-hour sampling point (t 4 ) were evaluated as potential predictors of irinotecan pharmacokinetics (36) . The midazolam concentration at the 4-hour sampling point is a commonly used parameter that has been extensively evaluated in limited sampling schemes to determine the reproducibility of estimating midazolam AUC by use of only one time point (37) .
Pharmacodynamic Evaluation
Complete blood cell counts and blood chemistry data were obtained for each patient before study entry and before each chemotherapy course, and these tests were repeated once a week during the patients' outpatient visits. If severe hematologic toxicity was detected, blood cell counts were measured daily or as clinically indicated. Diarrhea was scored by use of the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0 (available at: http://ctep.info.nih.gov/reporting/ctc.html [last accessed September 28, 2004] ).
Statistical Considerations
Pharmacokinetic data are presented as mean values and 95% confidence intervals (CIs), unless stated otherwise. Before genotype and phenotype analysis, AUC values were logarithmically transformed. Associations between irinotecan pharmacokinetics obtained during the first irinotecan treatment and the CYP3A phenotype as determined by the erythromycin breath test or the midazolam clearance test were evaluated by use of Pearson's correlation coefficient. The influence of the various genetic variants on irinotecan pharmacokinetics and pharmaco-dynamics during the first irinotecan treatment was assessed by use of a Kruskal-Wallis one-way analysis of variance or a nonparametric trend analysis. Although this study was mainly exploratory in intent, a Hochberg adjustment was used to evaluate the statistical significance of the multiple comparisons (38) . All statistical tests were two-sided. With both the KruskalWallis and the trend analysis tests, P values of less than .01 were regarded as statistically significant, and those less than .05 were considered a non-statistically significant trend (i.e., a PϽ.05 and Ն.01 corresponds with some evidence of difference, but the evidence is not strong enough to declare it to be statistically significant). These levels were chosen to reduce the risk of finding purely coincidental associations in view of the number of parameters analyzed. Statistical calculations were performed with SPSS version 10.1 (Paris, France) or Stata version 8.2 (Stata, College Station, TX). (Table 1 ). All but three of them received at least two courses of chemotherapy. The most frequent primary tumor types were lung cancer (n ϭ 10) and colorectal cancer (n ϭ 12). All patients received the planned fixed irinotecan dose of 600 mg during the first irinotecan treatment, but four of them received a 25% dose reduction during the second irinotecan treatment because of severe side effects experienced with the first administration, as required by the protocol.
RESULTS
Patients and Treatment
A total of 30 eligible adult white patients with cancer (16 males and 14 females) with a median age of 55 years (range ϭ 38 -73 years) were recruited to this study between January 1, 2002, and July 31, 2003
Irinotecan Disposition
Plasma concentrations of irinotecan, SN-38, and SN-38G as a function of time were accurately predicted by a modified version of a previous population model (35) , as determined by goodness-of-fit plots (data not shown). The typical irinotecan clearance was 31.8 L/h (95% CI ϭ 28.4 L/h to 35.1 L/h), the mean relative extent of irinotecan to SN-38 conversion was 0.0263 (95% CI ϭ 0.0218 to 0.0307), and the mean relative extent of SN-38 to SN-38G glucuronidation was 6.95 (95% CI ϭ 5.23 to 8.66), consistent with earlier data (Table 2 ) (35) . The interoccasion variability in irinotecan clearance was estimated to be 11.0%. The relative intrapatient variation in parameter estimates was minimal, with mean values for the ratio of the AUC in the second irinotecan treatment to the AUC in the first irinotecan treatment of 0.90, 0.87, and 0.86 for irinotecan, SN-38, and SN-38G, respectively. Conventional parameters for the erythromycin breath test (including the percentage of the administered dose in the sample obtained at the 20-minute point, the area under the CER curve from 0 to 40 minutes, and 1/t max ) were not statistically significantly associated with irinotecan clearance, the AUC of SN-38, or the relative extent of conversion (Table 3 ). In contrast, midazolam clearance (r ϭ .745, PϽ.001) and the midazolam concentration at the 4-hour sampling point (r ϭ Ϫ.416, P ϭ .022) were correlated with irinotecan clearance (Fig. 2 and Table  3 ). A sex difference in midazolam clearance was not observed (P ϭ .260). A weak correlation was found between the dosenormalized AUC values for midazolam and SN-38G (r ϭ .368, P ϭ .046). In contrast to earlier findings (39) , some of the erythromycin breath test parameters, including the percentage of the administered dose in the sample obtained at the 20-minute point and the area under the CER curve from 0 to 40 minutes, were statistically significantly correlated with midazolam clearance (r ϭ .529 and P ϭ .003 for the percentage of the administered dose in the sample obtained at the 20-minute point; and r ϭ .556 and P ϭ .001 for the area under the CER curve from 0 to 40 minutes) and the midazolam concentration at the 4-hour sampling point (r ϭ Ϫ.503 and P ϭ .005 for the percentage of ‫ء‬M, male; F, female; (N)SCLC, (non) small-cell lung cancer. †Miscellaneous include cervix cancer (n ϭ 2), breast cancer (n ϭ 1), cancer of head and neck (n ϭ 1), and adenocarcinoma of unknown primary (n ϭ 4). the administered dose in the sample obtained at the 20-minute point; and r ϭ Ϫ.653 and PϽ.001 for the area under the CER curve from 0 to 40 minutes).
Association of CYP3A Phenotype With Irinotecan Pharmacokinetics
Influence of Enzyme and Transporter Genotypes on Irinotecan Pharmacokinetics
Among the five genetic variants CYP3A4*2, CYP3A4*3, CYP3A4*17, CYP3A4*18, and CYP3A5*6, only the wild-type sequence was found, indicating that for these variants none of the patients in the studied cohort carried a mutant allele. The absence of these variants is consistent with previously published data obtained in the general European white population (40, 41) . For the other six variants (ABCB1*8, ABCB1*7, ABCB1*6, CYP3A4*1B, CYP3A5*3, and UGT1A1*28) studied, the frequency of the variant allele (q) was highly variable, with only four patients carrying at least one variant allele for CYP3A4*1B (allele frequency, 0.09) and as many as 29 patients carrying at least one variant allele for CYP3A5*3 (allele frequency, 0.87) ( Table 4 ).
The presence of two copies of the UGT1A1*28 allele was associated with statistically significantly altered pharmacokinetics of irinotecan. The UGT1A1*28 allele carries a seven-copy TA repeat (TA7) in the promoter region instead of a six-copy repeat (TA6), as in the wild-type UGT1A1 allele. The AUC of SN-38 was 435 ng · h/mL (95% CI ϭ 339 to 531 ng · h/mL) in wild-type patients (TA6/TA6; n ϭ 12), 631 ng · h/mL (95% CI ϭ 499 to 762 ng · h/mL) in heterozygous patients (TA6/TA7; n ϭ 15), and 1343 ng · h/mL (95% CI ϭ 0 to 4181 ng · h/mL) in homozygous variant patients (TA7/TA7; n ϭ 3) (P ϭ .006). Likewise, a UGT1A1*28 genotype-dependent relative extent of conversion was observed, with a value of 0.018 (95% CI ϭ 0.013 to 0.022) in wild-type patients, 0.030 (95% CI ϭ 0.025 to 0.034) in heterozygous patients, and 0.042 (95% CI ϭ 0 to 0.092) in homozygous variant patients (PϽ.001). Furthermore, the relative extent of glucuronidation was 9.27 (95% CI ϭ 6.00 to 12.53) in wild-type patients, 5.79 (95% CI ϭ 3.74 to 7.83; TA6/TA7) in heterozygous patients, and 3.48 (95% CI ϭ 0 to 9.47) in homozygous variant patients (P ϭ .010) (Fig. 3) . National Cancer Institute Common Toxicity Criteria scores of neutropenia (P ϭ .020), the observed nadir value of the absolute neutrophil count (P ϭ .026), and the percent decrease in absolute neutrophil count at nadir (P ϭ .024) were also associated with the UGT1A1*28 genotype. Statistically significant associations between irinotecan pharmacokinetics and the other variant genotypes studied were not observed, although the ABCB1*8 genotype was associated with a non-statistically significant trend in a decrease in the AUC of SN-38G (P ϭ .042, KruskalWallis test).
DISCUSSION
In this study, we tested the hypothesis that the pharmacokinetics of irinotecan can be predicted by the putative CYP3A phenotyping probes erythromycin and midazolam. We based the rationale for this investigation on the observations that irinotecan is a substrate for CYP3A4 and CYP3A5 (42) (Fig. 1) and that its pharmacokinetic profile is influenced by potent inhibitors (43) or inducers (44) of these isozymes. We hypothesized that by administering a probe drug substrate for the enzymes in question, enzymatic activity could be evaluated by comparing (metabolic) clearance and metabolic ratios of parent compounds and/or of their metabolites. Like irinotecan, erythromycin is a substrate for both CYP3A4 and ABCB1, but it is not metabo- lized by CYP3A5 (39) . In contrast, midazolam is metabolized by both CYP3A4 and CYP3A5, but it is a very poor substrate for ABCB1 (45) . Because irinotecan is also partially metabolized by CYP3A5 (42), we expected the pharmacokinetic correlations of irinotecan with erythromycin and midazolam to differ. Because the metabolic pathways of several other commonly used probes, such as the CYP3A phenotyping probes dextromethorphan and cortisol (16) , differ substantially from that of irinotecan, we did not evaluate them in this study. We did not observe statistically significant correlations between common parameters (CER 20 , area under the CER 0 -40, and 1/t max ) for the erythromycin breath test and irinotecan pharmacokinetics, but we did obtain a highly statistically significant correlation between midazolam clearance and irinotecan clearance. From this correlation analysis, we predict that, in the patient cohort in our study, 56% of total interindividual variability in irinotecan clearance can be explained by variation in CYP3A function. The discrepant findings between the erythromycin breath test and the midazolam clearance test may be related to the relatively slow and inefficient metabolism of midazolam, which more closely resembles the CYP3A-mediated metabolism of irinotecan than the fast and extensive CYP3A-mediated metabolism of erythromycin (39) . We also cannot exclude the possibility that ABCB1 plays a minor role in clearance of irinotecan and a larger role in the clearance of erythromycin and that this difference confounds pharmacokinetic interrelationships. We also observed a trend for a relationship between the AUC for midazolam and exposure to SN-38G. This finding was unexpected because SN-38G is formed from SN-38 through UGT1A-mediated conjugation that is independent of CYP3A activity. A possible explanation may be found in the indirect formation of SN-38 and SN-38G from 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin (NPC), which results from a ring-opening oxidation of the terminal piperidine ring of irinotecan that is mediated by CYP3A4 (46) (Fig. 1) .
Although irinotecan is considered a prodrug with little inherent antitumor activity, the ability to accurately predict its clearance may be clinically relevant. First, the etiology of irinotecan-mediated side effects is still not completely understood, and circulating concentrations of the parent drug may predict hematologic toxicity associated with irinotecan treatment (47) . Furthermore, the ratio of concentration of total unbound irinotecan to the concentration of total unbound SN-38 is similar to their potency ratio in vitro, and so both irinotecan and SN-38 are likely to be effective in vivo (5) . Second, SN-38 may be formed both peripherally in the intestines, liver, and blood, as well as in the tumor from the conversion of irinotecan by carboxylesterase 2 (hCE2), which may be more important than previously thought and may contribute to the variable response to irinotecan chemotherapy for solid tumors (48, 49) . Consequently, knowledge of phenotypic CYP3A activity, as a predictor of irinotecan clearance in individual patients, may help to reduce the pharmacokinetic and subsequent pharmacodynamic variability associated with irinotecan treatment.
We found that certain genetic variants in polymorphic proteins are associated with differences in the elimination of irinotecan or its metabolites, as predicted previously (50) . We also confirmed earlier preliminary observations that the UGT1A1*28 genotype is independently associated with the pharmacokinetic profile of irinotecan (51) (52) (53) and that ABCB1*8 has a smaller association (54) . Genotyping for CYP3A4 and CYP3A5 did not result in statistically significant correlations with irinotecan pharmacokinetics, perhaps because of the low allele frequency of most CYP3A variant genotypes (e.g., CYP3A4*17, CYP3A4*18, and CYP3A5*1) in the white population (40, 41) or because of the absence of a clinically important effect on enzyme activity in vivo (e.g., CYP3A4*1B) (55, 56) . Because CYP3A is a complex enzyme system that is easily influenced by environmental (i.e., comedication, herbal preparations, and/or food substances) and physiologic (i.e., aging, disease state, and altered liver and renal function) factors (5), the role of CYP3A genotyping in the chemotherapeutic treatment of cancer remains uncertain.
In conclusion, CYP3A phenotype (as determined by midazolam clearance) and UGT1A1*28 genotype appear to be statistically significant predictors of irinotecan and SN-38 pharmacokinetics, respectively. A prospective study to validate the usefulness of these phenotyping and genotyping strategies to optimize chemotherapeutic treatment with irinotecan for individual patients is currently under way. In addition, limited sampling strategies are being developed by use of data obtained in a larger cohort of patients to further optimize the clinical applicability of the midazolam clearance test. 
